Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis.
Publication/Presentation Date
1-1-2020
Abstract
BACKGROUND: The current standard of care for the management of patients with newly diagnosed glioblastoma (GBM) includes maximal safe resection followed by radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ). While it is well established that TMZ has better efficacy in patients with
METHODS: We conducted a systematic review and meta-analysis to provide separate estimates of median overall survival (OS) and progression-free survival (PFS) for patients with methylated and unmethylated GBM treated with RT with or without TMZ. We searched multiple databases from inception to January 13, 2020.
RESULTS: The median OS for patients with unmethylated GBM treated with RT/TMZ pooled from 5 phase III studies (
CONCLUSIONS: This meta-analysis provides estimates of survival for patients with
Volume
2
Issue
1
First Page
082
Last Page
082
ISSN
2632-2498
Published In/Presented At
Alnahhas, I., Alsawas, M., Rayi, A., Palmer, J. D., Raval, R., Ong, S., Giglio, P., Murad, M. H., & Puduvalli, V. (2020). Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis. Neuro-oncology advances, 2(1), vdaa082. https://doi.org/10.1093/noajnl/vdaa082
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
33150334
Department(s)
Administration and Leadership
Document Type
Article